Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21

Karyopharm announces updated Xpovio data in multiple myeloma

Karyopharm Therapeutics announced that two presentations highlighting new and updated data relating to Xpovio will be given at the American Society of Hematology Annual Meeting. The first study describes updated data from the Phase 1b/2 Stomp study evaluating the all oral regimen of selinexor in combination with Pomalyst and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. The second abstract describes new data on the use of selinexor and dexamethasone, either alone or in combination with standard approved therapies, in patients with multiple myeloma whose disease has progressed following experimental chimeric antigen receptor T-cell therapy. "We continue to be pleased with the efficacy and safety observed in the all oral selinexor plus Pomalyst arm of the Phase 1b/2 STOMP study, where patients with Pomalyst-naive and Revlimid (lenalidomide)-relapsed or -refractory myeloma achieved a 56% overall response rate and a 12-month progression free survival," said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. "Another key study this year is the presentation of new data from patients treated with selinexor-based regimens after their myeloma had progressed following experimental CAR-T therapy. Although these data are early, six of seven patients whose disease relapsed after CAR-T achieved a response when treated with selinexor and dexamethasone alone or in combination with either Velcade or Kyprolis. There is currently very limited data regarding treatment options for patients whose disease has progressed following experimental CAR-T therapy, and we believe these encouraging results further reinforce the therapeutic activity of selinexor in patients with relapsed or refractory disease."

  • 07

    Dec

KPTI Karyopharm
$16.30

-1.15 (-6.59%)

07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/19
BARD
09/24/19
NO CHANGE
Target $25
BARD
Outperform
Karyopharm Xpovio launch appears strong, says Baird
Baird analyst Michael Ulz said his physician survey regarding the Karyopharm launch of Xpovio is indicating strong early trends. The analyst said there appears to be an early robust, broad adoption with meaningful share gains ahead, and the safety profile is manageable. Ulz said he sees upside to estimates and he reiterated his Outperform rating and $25 price target on Karyopharm shares.
11/05/19
HCWC
11/05/19
NO CHANGE
Target $36
HCWC
Buy
Karyopharm price target raised to $36 from $32 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Karyopharm Therapeutics to $36 from $32 following the company's Q3 results. The analyst believes the Xpovio launch started strong and he keeps a Buy rating on the shares.
11/06/19
WEDB
11/06/19
NO CHANGE
Target $18
WEDB
Outperform
Karyopharm price target raised to $18 from $15 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Karyopharm to $18 from $15, citing abetter-than-expected XPOVIO launch in penta-refractorymultiple myeloma that highlights the high unmet need for novel, differentiated therapies for the cancer. In both the U.S. and EU combined, Nierengarten sees XPOVIO approaching $300M in net sales in penta-refractory MMalone, with an additional greater than$350M opportunity in earlier lines of therapy, he tells investors in a research note. He maintains an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BT

BT Group

$0.00

(0.00%)

, GOOG

Alphabet

$1,461.36

9.42 (0.65%)

11:42
01/17/20
01/17
11:42
01/17/20
11:42
Hot Stocks
BT partners with Google to include Stadia in broadband bundles »

BT Group (BT) said via…

BT

BT Group

$0.00

(0.00%)

GOOG

Alphabet

$1,461.36

9.42 (0.65%)

GOOGL

Alphabet Class A

$1,459.67

9.84 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

PLAY

Dave & Buster's

$46.14

4.085 (9.71%)

11:39
01/17/20
01/17
11:39
01/17/20
11:39
Recommendations
Dave & Buster's analyst commentary  »

Stifel wouldn't be a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

FB

Facebook

$220.95

-0.83 (-0.37%)

11:37
01/17/20
01/17
11:37
01/17/20
11:37
Periodicals
Facebook cuts Oculus Go price to $149 from $199, UploadVR reports »

Facebook said that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

WMT

Walmart

$115.15

-0.74 (-0.64%)

11:36
01/17/20
01/17
11:36
01/17/20
11:36
Hot Stocks
Walmart U.S. names Dacona Smith as incoming COO »

Walmart U.S. says Dacona…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

GOOGL

Alphabet Class A

$1,461.15

11.32 (0.78%)

, GOOG

Alphabet

$1,462.70

10.76 (0.74%)

11:33
01/17/20
01/17
11:33
01/17/20
11:33
Periodicals
Google working to bring Steam support to Chromebooks, Android Police says »

Kan Liu, director of…

GOOGL

Alphabet Class A

$1,461.15

11.32 (0.78%)

GOOG

Alphabet

$1,462.70

10.76 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

WMT

Walmart

$115.30

-0.59 (-0.51%)

11:28
01/17/20
01/17
11:28
01/17/20
11:28
Periodicals
Walmart chief merchant Steve Bratspies to depart, WSJ reports »

Walmart chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

NFLX

Netflix

$339.15

0.48 (0.14%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Hot Stocks
Netflix opens new Paris office, boosts investment in France »

Netflix announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

11:25
01/17/20
01/17
11:25
01/17/20
11:25
General news
Philly Fed's Harker said the economy is looking "pretty good," »

Philly Fed's Harker…

AMED

Amedisys

$180.60

-0.59 (-0.33%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Conference/Events
Amedisys participates in a conference call with Benchmark »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

IBM

IBM

$137.15

-0.85 (-0.62%)

, PINS

Pinterest

$23.11

0.15 (0.65%)

11:24
01/17/20
01/17
11:24
01/17/20
11:24
On The Fly
IBM downgrade, Pinterest upgrade among today's top analyst calls »

Check out today's top…

IBM

IBM

$137.15

-0.85 (-0.62%)

PINS

Pinterest

$23.11

0.15 (0.65%)

EBAY

eBay

$35.69

-0.22 (-0.61%)

TWTR

Twitter

$34.11

-0.08 (-0.23%)

SNAP

Snap

$19.10

0.85 (4.66%)

QCOM

Qualcomm

$95.08

3.305 (3.60%)

WDC

Western Digital

$68.69

0.07 (0.10%)

LUV

Southwest

$55.31

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

NCLH

Norwegian Cruise Line

$59.43

0.84 (1.43%)

11:21
01/17/20
01/17
11:21
01/17/20
11:21
Periodicals
Breaking Periodicals news story on Norwegian Cruise Line »

Hedgeye names Norwegian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/17/20
01/17
11:17
01/17/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/17/20
01/17
11:16
01/17/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$7.45

-0.49 (-6.17%)

11:15
01/17/20
01/17
11:15
01/17/20
11:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.